Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADCT-502 in advanced solid tumors with HER2 expression
NCT03125200Phase 1Terminated
- Sponsor
- ADC Therapeutics
- Start
- May 2017
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ADCT-502 in breast cancer, non-small cell lung cancer (NSCLC), gastroesophageal junction cancer and 2 more, sponsored by ADC Therapeutics. Primary endpoints: Dose-Limiting Toxicities, Treatment Emergent Adverse Events and 1 more. Started May 2017; status: terminated.
02
Drugs
ADCT-502
03
Conditions
breast cancernon-small cell lung cancer (NSCLC)gastroesophageal junction cancerbladder cancersolid tumor
Beyond the preview
Go deeper on NCT03125200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03125200.